• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BioCorRx partners with virtual reality center for naltrexone implant study

June 1, 2017 By Sarah Faulkner

BioCorRxBioCorRx (OTC:BICX) said today that it partnered with the Virtual Reality Medical Center to conduct a study on the company’s long-lasting naltrexone implant.

BioCorRx’s recovery program consists of a long-lasting implant that delivers an opioid antagonist, naltrexone, which reduces physical cravings for alcohol and opioids. The recovery service also has a counseling program specifically designed to treat alcohol and substance abuse addictions in people receiving long-term naltrexone therapy.

The Virtual Reality Medical Center said it plans to conduct studies at its office in the Scripps Memorial Hospital Campus and pursue additional grant funding from the National Institutes of Health to support more work related to BioCorRx’s implant.

“We are honored to be working with such highly respected doctors at Scripps Memorial Hospital, a premier medical facility. They will be helping us set up and conduct the study on our naltrexone implant and recovery program for alcohol and opioid addictions with the goal of validating the program’s effectiveness to the broader medical community,” BioCorRx’s president, CEO & director Brady Granier said in prepared remarks. “We believe that by conducting this study, we will gain even more 3rd-party support for our program which has already helped countless individuals over the years. Not only can this study be helpful for educating practitioners, but it may also help lay the foundation for broader national awareness and reimbursement. They will also be assisting us with grant submissions, which could support future research on our naltrexone products. Dr. Shurman is also a valuable addition to our team. Not only is he going to assist Drs. Mark and Brenda Wiederhold with the studies, but he will provide key introductions to potential strategic partners and healthcare professionals in the pain management and addiction fields.”

“We are pleased to work with BioCorRx in developing strategies to combat an issue that has become a national priority,” Dr. Brenda Wiederhold, VRMC president, said.

“The ability to strategically combine both pharmacological and technical interventions is clearly the future to successfully addressing the crisis in opioid addiction,” VRMC CEO Dr. Mark Wiederhold added.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Wall Street Beat Tagged With: BioCorRx

IN CASE YOU MISSED IT

  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS